Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00362817|
Recruitment Status : Completed
First Posted : August 10, 2006
Results First Posted : May 6, 2015
Last Update Posted : June 1, 2017
|Condition or disease||Intervention/treatment||Phase|
|Brain Tumor Brain Metastases||Drug: carboplatin Drug: temozolomide||Phase 1 Phase 2|
Rationale: Surgery and radiation are often used as treatments for brain metastases, or tumors in the brain that originate from other parts of the body. It is currently unknown whether patient survival or time to progression would experience additional benefits through the addition of chemotherapy. Previous research does appear to suggest that a chemotherapy regimen may improve outcomes of patients with brain metastases previously treated with radiation. The current study further evaluates this research question by providing patients with recurrent or symptomatic residual brain metastases with carboplatin and temozolomide, two chemotherapy agents. Temozolomide has demonstrated clinical antitumor efficacy against malignant gliomas and has been tested with some efficacy against several other types of cancer. This drug appears to have less adverse effects compared to other commonly used cancer drugs. Recent research indicates that temozolomide also has some efficacy against brain metastases. In addition, previous research indicates carboplatin's lack of severe toxicity in patients with this disease.
Treatment: Study participants will be treated with carboplatin and temozolomide. Carboplatin will be administered through intravenous infusions. Temozolomide will be given through oral pills. Before these drugs are administered, study participants will undergo a pre-treatment evaluation with physical and neuropsychological examinations, neuro-imaging, laboratory tests, quality of life assessment, and other procedures. Carboplatin will be given for two consecutive days. Temozolomide will be taken by study participants daily for five consecutive days. Both of these treatment schedules will be repeated every 28 days. Several tests and exams will be given throughout the study to closely monitor patients. Study treatments will be discontinued due to disease growth or unacceptable adverse events.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||17 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I/II Multicenter Trial of Intra-Arterial Carboplatin and Oral Temozolomide for the Treatment of Recurrent and Symptomatic Residual Brain Metastases.|
|Actual Study Start Date :||October 2004|
|Actual Primary Completion Date :||January 2008|
|Actual Study Completion Date :||February 2008|
Experimental: Temozolomide & Intra-Arterial (IA) carboplatin
Patients will be administered Temozolomide orally once a day for 5 consecutive days and and will receive Intra Arterial Carboplatin
IA carboplatin 200 mg/m2/day for each arterial injection on days 1 and 2.
150 mg/m2/day orally Days 1-5. Treatment cycles to be repeated every 4 weeks.
Other Name: Temodar
- Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide [ Time Frame: up to 1 year ]Response was evaluated by MRI Criteria (MacDonald Criteria). The MacDonald criteria for determining tumor progression is determined through assessing the increase in size of an enhancing tumor on consecutive MRI scans and clinical assessment. Complete response occurs when there is a disappearance of all enhancing tumor on consecutive MRI scans at least one month apart. Partial response occurs at a >50% reduction in size of enhancing tumor on consecutive MRI scans at least one month apart. Progressive disease occurs when there is a >25% increase in size of enhancing tumor on consecutive MRI scans. Stable disease occurs in all remaining situations.
- Analyze Patients Time to Progression [ Time Frame: up to 60 weeks ]
Responses to treatment was determined by comparing new enhanced MRI scans with those obtained at the previous evaluation (i.e., 2 treatment cycles ago) or with the pre-IA chemotherapy baseline scan, if it is the first follow-up MRI scan during treatment.
MRI is the neuro-imaging modality of choice, since it is more accurate than CT for small tumors, multiple tumors, and tumors in the posterior fossa.58 The methodology used (techniques and equipment) must be identical for all scans. Lesions should be measured as the largest diameter seen on scan and the largest diameter perpendicular to that dimension.
- Determine the Overall Survival of Patients [ Time Frame: up to 64 weeks ]From the time of protocol initiation
- Determine the Cause of Death of Patients After Treatment [ Time Frame: up to 1 year ]To determine the cause of death (i.e., CNS tumor versus systemic disease progression) in patients after treatment.
- The Incidence and Severity of Centeral Nervous System (CNS) Toxicities [ Time Frame: up to 24 weeks ]To determine the incidence and severity of CNS toxicity in patients treated with intra-arterial carboplatin and oral temozolomide.
- Quality of Life Assessment [ Time Frame: up to 2 years ]To determine the impact of treatment on quality of life.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00362817
|United States, Ohio|
|Ohio State University|
|Columbus, Ohio, United States, 43210|
|Principal Investigator:||Herbert Newton, MD||Ohio State University|